OLUMIANT
PeakNDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
OLUMIANT by Eli Lilly and Company is (jak) inhibitor. Approved for moderately to severely active rheumatoid arthritis in adults, more tumor necrosis factor (tnf) blockers, coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen and 5 more indications. First approved in 2018.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLUMIANT (baricitinib) is an oral Janus Kinase (JAK) inhibitor approved by the FDA in May 2018 for treating inflammatory and autoimmune conditions. It works by selectively inhibiting JAK enzymes, which play a key role in cytokine signaling pathways that drive inflammation. The drug is administered as an oral tablet, offering convenience over injectable biologics.
Peak6.1 years to LOE
OLUMIANT is in peak commercial maturity; brand teams are focused on market penetration and indication expansion rather than launch activities, suggesting stable mid-sized team structure.
Mechanism of Action
(JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate…
Indications (8)
Worked on OLUMIANT at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.